United States-based Dragonfly Therapeutics Inc has expanded its collaboration with Bristol Myers Squibb, a United States-based pharmaceutical company, to discover and produce Dragonfly's immunotherapies for multiple sclerosis and neuro-inflammation targets, it was reported on Monday.
According to the contract, Dragonfly is to offer Bristol Myers Squibb the option to license global intellectual property rights to multiple candidates produced utilising Dragonfly's proprietary platform for multiple new targets.
The deal includes an upfront payment of USD55m to Dragonfly from Bristol Myers Squibb, while Dragonfly will be eligible to receive additional payments associated with development, regulatory and sales milestones and potential royalties on sales of approved products.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007